A Pilot Study to Assess the Use of Methylone in the Treatment of Post-Traumatic Stress Disorder PTSD

• Research type

  Research Study

• Full title

  A Pilot Study to Assess the Use of Methylone in the Treatment of Post-Traumatic Stress Disorder (PTSD)

• IRAS ID

  1005407

• Contact name

  Martin Stogniew

• Contact email

  martin@transcendtherapeutics.com

• Sponsor organisation

  Transcend Therapeutics, Inc.

• Eudract number

  2022-000484-42

• Clinicaltrials.gov Identifier

  NCT05741710

• Research summary

  Methylone is a new and potentially effective treatment option for participants with post traumatic stress disorder (PTSD). This is a randomised, double-blind, parallel-group, placebo-controlled assessment of methylone for the management of the symptoms of PTSD. This multi-centre study will be conducted in up to 7 sites in the United Kingdom.
  The study will enroll up to 64 evaluable participants, aged between 18 to 65 years, inclusive, with PTSD in the UK. There are 4 planned weekly dose sessions for each participant.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  22/LO/0306

• Date of REC Opinion

  28 Jul 2022

• REC opinion

  Further Information Favourable Opinion